ArticleMicrobiologyOpen2020
Penicillin-binding protein PBP2a provides variable levels of protection toward different β-lactams in Staphylococcus aureus RN4220.
Article in MicrobiologyOpen, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 56 citations in OpenAlex.
- Review
- Preparation and Physicochemical Characterization of Chitosan-Coated Iron Oxide Nanoparticles Conjugated with Oxacillin: Antimicrobial, Antibiofilm, and Biocompatibility Activities against MRSA Staphylococcus aureus.Applied biochemistry and biotechnology · 2026Article
- Berberine Synergistically Enhances the Antibacterial Activity of Ampicillin against Ampicillin-ResistantACS omega · 2026Article
- Methicillin-ResistantInternational journal of molecular sciences · 2026Review
- Antibacterial Potential ofFoods (Basel, Switzerland) · 2026Article
- Tetrahedral framework nucleic acid delivery of emodin enables precision antibacterial and anti-inflammatory therapy for drug-resistant Staphylococcus aureus.Journal of nanobiotechnology · 2026Article
- Thymoquinone combined with conventional antibiotics against pandrug-resistantFrontiers in pharmacology · 2026Article
- Antibiotic-Induced Bacterial Cell Death: A "Radical" Way of Dying?Current topics in microbiology and immunology · 2025Article
- Deciphering meropenem persistence inAntimicrobial agents and chemotherapy · 2025Article
- Chemical Profiling and Antibacterial Potential of Methanol Extract ofCurrent topics in medicinal chemistry · 2025Article
- Evaluation of Antibiotic Resistance Mechanisms in Gram-Positive Bacteria.Antibiotics (Basel, Switzerland) · 2024Review
- Detection of the methicillin-resistantOpen veterinary journal · 2024Article
- Spread of livestock-associated methicillin-resistantOpen veterinary journal · 2024Review
- Integrating multi-wet laboratory diagnostics to study staphylococci in animals in Uganda.BMC microbiology · 2024Article
- Synthesis, Antibacterial Effects, and Toxicity of Licochalcone C.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Cephalosporin resistance, tolerance, and approaches to improve their activities.The Journal of antibiotics · 2024Review
- Chiral phthalimides against penicillin-binding protein 2a of methicillin-resistantFrontiers in pharmacology · 2024Article
- Kinship analysis ofVeterinary world · 2024Article
- Genetics of antibiotic resistance in methicillin-resistantBiotechnologia · 2024Review
- In Vitro Synergistic Inhibitory Effects of Plant Extract Combinations on Bacterial Growth of Methicillin-ResistantPharmaceuticals (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) is resistant to most β-lactams due to the expression of an extra penicillin-binding protein, PBP2a, with low β-lactam affinity. It has long been known that heterologous expression of the PBP2a-encoding mecA gene in methicillin-sensitive S. aureus (MSSA) provides protection towards β-lactams, however, some reports suggest that the degree of protection can vary between different β-lactams. To test this more systematically, we introduced an IPTG-inducible mecA into the MSSA laboratory strain RN4220. We confirm, by growth assays as well as single-cell microfluidics time-lapse microscopy experiments, that PBP2a expression protects against β-lactams in S. aureus RN4220. By testing a panel of ten different β-lactams, we conclude that there is also a great variation in the level of protection conferred by PBP2a. Expression of PBP2a resulted in an only fourfold increase in minimum inhibitory concentration (MIC) for imipenem, while a 32-fold increase in MIC was observed for cefaclor and cephalexin. Interestingly, in our experimental setup, PBP2a confers the highest protection against cefaclor and cephalexin-two β-lactams that are known to have a high specific affinity toward the transpeptidase PBP3 of S. aureus. Notably, using a single-cell microfluidics setup we demonstrate a considerable phenotypic variation between cells upon β-lactam exposure and show that mecA-expressing S. aureus can survive β-lactam concentrations much higher than the minimal inhibitory concentrations. We discuss possible explanations and implications of these results including important aspects regarding treatment of infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.